scholarly journals In vivo detection of clinically non-apparent ocular surface inflammation in patients with meibomian gland dysfunction-associated refractory dry eye symptoms: a pilot study

Eye ◽  
2015 ◽  
Vol 29 (8) ◽  
pp. 1099-1110 ◽  
Author(s):  
Y Qazi ◽  
A Kheirkhah ◽  
C Blackie ◽  
A Cruzat ◽  
M Trinidad ◽  
...  
Keyword(s):  
Pilot Study ◽  
Dry Eye ◽  
Ocular Surface ◽  
Meibomian Gland ◽  
In Vivo Detection ◽  
Eye Symptoms ◽  
Surface Inflammation ◽  
Ocular Surface Inflammation ◽  
Dry Eye Symptoms

scholarly journals Investigation of Meibomian Gland Function and Dry Eye Disease in Patients with Graves’ Ophthalmopathy

2020 ◽  
Vol 9 (9) ◽  
pp. 2814
Author(s):  
Sachiko Inoue ◽  
Motoko Kawashima ◽  
Reiko Arita ◽  
Ai Kozaki ◽  
Kazuo Tsubota
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Normal Subjects ◽  
Meibomian Gland ◽  
Clinical Activity ◽  
Upper Eyelid ◽  
Graves Ophthalmopathy ◽  
Related Quality ◽  
Eye Symptoms ◽  
Dry Eye Symptoms

We prospectively evaluated the relationship between meibomian gland dysfunction (MGD) and Graves’ ophthalmopathy (GO) in 19 patients (38 eyes) with subjective dry eye symptoms, compared to 14 age-matched normal participants (14 eyes). Extraocular muscle and lacrimal gland enlargement were evaluated by magnetic resonance imaging (MRI). Ocular surface examinations included fluorescein staining for keratoconjunctival epithelial damage, tear breakup time (TBUT) evaluation, and Schirmer’s test. Dry eye symptoms were evaluated with the Dry Eye-related Quality-of-Life Score (DEQS) questionnaire. Lid-margin abnormalities, meibum grade, and meiboscores were assessed using meibography. Clinical activity scores and T2 signal intensity ratios were used to define GO activity. All GO patients had obstructive MGD and 79% exhibited levator muscle enlargement. Ocular surface parameters of TBUT (p = 0.000), meibum score (p = 0.000), eyelid vasculitis (p = 0.000), meiboscore of the upper lid (p = 0.002), total meiboscores (p = 0.001), and DEQS (p = 0.000) significantly differed between GO patients and normal subjects. In addition, GO patients had significantly more abnormalities of the central region of the upper eyelid than normal subjects (p = 0.000). Thus, MGD might be related to eye discomfort and deterioration of the ocular surface in GO patients. Inflammation and morphological meibomian gland changes might be characteristic of GO.

scholarly journals Prevalence and Risk Factors of Severe Dry Eye in Bangladesh-Based Factory Garment Workers

Diagnostics ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 634 ◽  
Author(s):  
Mamunur AKM Rashid ◽  
Calesta Hui Yi Teo ◽  
Sumaiya Mamun ◽  
Hon Shing Ong ◽  
Louis Tong
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Age Groups ◽  
Meibomian Gland ◽  
Ocular Surface Disease Index ◽  
Cross Sectional ◽  
Garment Workers ◽  
Severity Grading ◽  
Eye Symptoms ◽  
Dry Eye Symptoms

This study sought to evaluate the prevalence of dry eye and meibomian gland dysfunction (MGD) and the associated factors of severe dry eye symptoms (SDES) among garments worker of Gazipur, Bangladesh. We prospectively collected cross-sectional data for 1050 garments workers of a factory (70% response). All participants had an evaluation of the Ocular Surface Disease Index (OSDI), and a detailed ophthalmic examination including tear breakup time (TBUT), ocular surface fluorescein staining, and Schirmer’s I test. MGD grading was based on the viscosity/color and ease of manual expression of meibum. Mean age of participants was 35.5 ± 12.1 years; 53.8% were women. The prevalence of dry eye (OSDI > 12) was 64.2% (95% CI 61.2–67.1%). OSDI was not significantly different between sex or age-groups but associated with increasing MGD grade (p < 0.001), reduced TBUT (<5 s) [p < 0.001], and reduced Schirmer’s test (<5 mm) [p < 0.001]. Thirty-five percent had SDES (OSDI > 32). Using univariate logistic regressions, SDES was associated with older age (Odds Ratio (OR) 1.01, 95% Confidence Interval [1.005–1.03] per year increase) and male sex (OR 1.76, 95% CI: 1.36–2.27). When adjusted for age and sex, SDES were strongly associated with increase in MGD severity grading (OR 188, 95% CI: 91–390). However, in multivariate regression, TBUT, but not MGD severity, became the only significant determinant of SDES (OR 13.0, 95% CI: 6.3–27.0, for every 1 s decrease in TBUT). MGD is common in garments workers, contributing to dry eye symptoms in addition to other tear parameters. Reduced tear stability is associated with SDES.

Is there a role for tapered topical dose steroidal treatment for dry eye disease? A randomized, pilot study

2021 ◽  
pp. 112067212110487
Author(s):  
Stefano Barabino ◽  
Elisa Montaldo ◽  
Maria Cristina Mingari ◽  
Cosimo Mazzotta ◽  
Sebastiano Giuffrida ◽  
...  
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Loteprednol Etabonate ◽  
Hla Dr ◽  
Eye Symptoms ◽  
Conjunctival Cells ◽  
Surface Inflammation ◽  
Ocular Surface Inflammation

Purpose: To evaluate the effect of tapered doses of loteprednol-etabonate in dry eye disease patients. Materials and methods: Dry eye and treatment outcomes were assessed by Schirmer I test, tear BUT, lissamine green conjunctival staining, fluorescein corneal staining, and HLA-DR expression on conjunctival cells. Patients received either loteprednol-etabonate 0.5% twice daily for 14 days tapered to once daily for 14 days, and then twice weekly for 28 days ( n = 10), or NaCl 0.9%. Results: A significant decrease of ocular surface inflammation and improvement of symptoms was recorded in the study group compared with controls at days 14 and 56. Change from baseline in HLA-DR expression in CD45+ conjunctival cells was significantly higher in treated patients at day 14. Intraocular pressure and best corrected visual acuity were preserved in all treated eyes. Conclusions: Tapered doses of loteprednol etabonate 0.5% suspension controlled ocular surface inflammation, improving dry eye symptoms.

Optimum | Tangible Hydra-PEG™ – Gaining Momentum in the Industry

The Eye ◽  
2021 ◽  
Vol 23 (4) ◽  
pp. 31-34
Author(s):  
M. Conway
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Surface Coating ◽  
Clinical Case ◽  
Contact Lenses ◽  
Ocular Surface Disease ◽  
Corneal Ectasia ◽  
Corneal Lens ◽  
Eye Symptoms ◽  
Dry Eye Symptoms

The issue of hydrophilicity of the surface of gas permeable contact lenses remains one of the persistent problems. Tangible Hydra-PEG™ surface coating is applied to gas permeable contact lenses to significantly improve wettability and wearing comfort. Although it is mainly used to alleviate dry eye symptoms in scleral and corneal lens users, particularly for those patients with corneal ectasia and/or Ocular Surface Disease (OSD), it can be used in other modalities. This article describes the development of the product and describes the benefits of its use in a clinical case.

TEAR FILM EVALUATION IN CASES OF PARKINSON’S DISEASE

2021 ◽  
pp. 22-24
Author(s):  
V. Meenakshi ◽  
Saswathi Bhushan ◽  
T. Jyothirmayi
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dry Eye ◽  
Meibomian Gland ◽  
Blink Rate ◽  
Eye Symptoms ◽  
Tear Meniscus ◽  
Tear Meniscus Height ◽  
Dry Eye Symptoms ◽  
Meibomian Gland Disease

AIM: To evaluate tear lm status in cases of Parkinson's Disease and compare with a study group METHODS:50 patients of Parkinson's Disease and 50 age-gender matched controls were included in this study. Both groups underwent detailed history regarding dry eye symptoms,tear lm evaluation using slit-lamp bio-microscopy, uorescein staining, tear meniscus height, tear breakup time, Schirmer test, blink rate. Statistical analysis was done with Statistical Package for Social Sciences [SPSS] - Version 22.0 Released 2013 version RESULTS: There was a signicant difference between the various groups in terms of distribution of Meibomian Gland Disease 72.0% of the Case group as compared to 40% of control group had Meibomian Gland Disease,There was a signicant difference between the various groups in terms of distribution of Tear Meniscus Height <0.25Mm , Case group had the larger proportion of Tear Meniscus Height of <0.25Mm .There was a signicant difference between the various groups in terms of distribution of Tear Breakup Time <5 Sec, Schirmer's Test <5Mm in 5Min and Blink Rate <10 .There was no signicant difference between the various groups in terms of distribution of corneal Staining and dry eye symptoms. CONCLUSION: The study concluded that patient of Parkinson's disease had higher dry eye symptoms and Meibomian gland disease Also they have reduced Tear miniscus height,Tear lm break up time,Schirmer test I and Blink rate

scholarly journals One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease

2017 ◽  
Vol 27 (6) ◽  
pp. 678-685 ◽  
Author(s):  
Christophe Baudouin ◽  
Maite Sainz de la Maza ◽  
Mourad Amrane ◽  
Jean-Sébastien Garrigue ◽  
Dahlia Ismail ◽  
...  
Keyword(s):  
Dry Eye ◽  
Cyclosporine A ◽  
Ocular Surface ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Efficacy And Safety ◽  
Open Label ◽  
Once Daily ◽  
Surface Inflammation ◽  
Ocular Surface Inflammation

Purpose The SANSIKA study evaluated the efficacy/safety of 0.1% (1 mg/mL) cyclosporine A cationic emulsion (CsA CE) for treating dry eye disease (DED) with severe keratitis. The double-masked phase demonstrated that CsA CE was effective in reducing corneal damage and ocular surface inflammation, and was well-tolerated over 6 months. Here we report efficacy and safety findings of SANSIKA's open-label extension (OLE). Methods In this multicenter, double-masked, phase III study, patients with severe DED (corneal fluorescein staining [CFS] grade 4, modified Oxford scale) were randomized to once-daily CsA CE (Ikervis®) or its vehicle for 6 months, followed by 6-month open-label, once-daily CsA CE (CsA CE/CsA CE and vehicle/CsA CE groups). Results A total of 177 patients completed the OLE. Efficacy results reiterated the double-masked phase: CsA CE reduced CFS score and human leukocyte antigen-antigen D related expression, improved corneal clearing, and produced continuous improvements in global symptom scores (ocular surface disease index [OSDI], visual analogue scale). The CFS-OSDI response rates (≥2 CFS points, ≥30% OSDI improvement vs baseline) at 12 vs 6 months were 39.1% vs 28.6%, respectively, for CsA CE/CsA CE and 38.0% vs 23.1% for vehicle/CsA CE. Cyclosporine A CE's safety profile was similar to the initial 6 months. The most common treatment-related treatment-emergent adverse event was instillation site pain (7.8%, CsA CE/CsA CE group; 19.0%, vehicle/CsA CE group). No unexpected safety signals were observed; systemic CsA levels were undetectable/negligible in all patients except 2 previously treated with systemic CsA. Conclusions In this 12-month study, once-daily CsA CE was well-tolerated and showed reductions in ocular surface inflammation and improvements in signs/symptoms in DED patients with severe keratitis.

Sign in / Sign up

Export Citation Format

Share Document